Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2546-2553

  Purkins, L ^a   Wood, N ^a   Ghahramani, P ^a   Greenhalgh, K ^a   Allen, M J ^a   Kleinermans, D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE; ALANINE AMINOTRANSFERASE; ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG TOLERABILITY; FOLLOW UP; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; MYCOSIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STEADY STATE; TREATMENT PLANNING; VISUAL IMPAIRMENT; ADOLESCENT; AREA UNDER THE CURVE; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; METABOLISM; ORAL DRUG ADMINISTRATION; SALIVA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIFUNGAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMAN; INJECTIONS, INTRAVENOUS; LIVER FUNCTION TESTS; MALE; PYRIMIDINES; SALIVA; TRIAZOLES; HUMANS;

EID: 0035991878     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2546-2553.2002     Document Type: Article

References (12)

1. In vitro studies of two triazole antifungal agents (UK-109,496 and fluconazole) against Candida species
2. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
3. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
4. Biochemistry and molecular biology of the human CYP2C subfamily
5. The search for new triazole antifungal agents
6. In vitro evaluation of voriconazole against some clinically important fungi
7. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
8. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates
9. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
10. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
11. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei